Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

SRTA - Strata Critical Medical, Inc. So'nggi... | Finranks

Home

SRTA

S

Strata Critical Medical, Inc. (SRTA)

NCM – Real vaqt narxi. Valyuta: USD

4.14

-0.11 (-2.59%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

4.17

+0.03 (0.72%)

Bozordan keyin: Mar 27, 2026, 7:50 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth

Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth

Strata Critical Medical is rated 'Buy' with a 12–24 month horizon, targeting 30–35% upside as valuation remains attractive despite a recent rally. SRTA's transformation into a pure-play medical logistics provider, robust FY25 results, and margin expansion underpin confidence in forward guidance. Industry tailwinds, regulatory catalysts, and an aggressive acquisition strategy position SRTA for sustained revenue and EBITDA growth, with FY26 guidance implying an 11.6% EBITDA margin.

Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript

Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript

Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript

Strata Critical Medical Announces Fourth Quarter 2025 Results

Strata Critical Medical Announces Fourth Quarter 2025 Results

Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025 Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata's organic growth Full year 2025 net loss from continuing operations was $20.1 million Full year 2025 revenue and Adjusted EBITDA (1) of $197.1 million and $14.1 million, respectively, both beat the high end of our guidance range Raising full year 2026 revenue guidance to between $260 and $275 million and Adjusted EBITDA guidance to between $29 and $33 million (2) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the fourth quarter ended December 31, 2025. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.

Strata Critical Medical Schedules Fourth Quarter 2025 Earnings Conference Call

Strata Critical Medical Schedules Fourth Quarter 2025 Earnings Conference Call

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and will include a question-and-answer session for call participants.

Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditions Owned aircraft excluded from collateral package and remain unencumbered NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate of $50.0 million (the “ABL Facility”).

Strata Critical Medical: Likely Valuation Re-Rating After Q4 Earnings (Upgrade)

Strata Critical Medical: Likely Valuation Re-Rating After Q4 Earnings (Upgrade)

Strata Critical Medical, Inc. is refocused on organ transplant logistics after divesting its air passenger business, positioning for higher-margin, long-term growth. SRTA's acquisition of Keystone Perfusion fills a key service gap, boosting market share to 13% and enabling full-stack, technology-agnostic offerings in organ preservation. Keystone's strong FCF conversion (80%) and rapid revenue growth (45% YoY) are expected to drive SRTA's margin expansion and profitability from 2026 onward.

Strata Critical Medical, Inc. (SRTA) Analyst/Investor Day Transcript

Strata Critical Medical, Inc. (SRTA) Analyst/Investor Day Transcript

Strata Critical Medical, Inc. ( SRTA ) Analyst/Investor Day November 17, 2025 2:00 PM EST Company Participants Mathew Schneider - Vice President of Investor Relations & Strategic Finance Melissa Tomkiel - Co- CEO, General Counsel & Director William Heyburn - Co- CEO, CFO & Director Scott Wunsch - Chief Executive Officer of Trinity Keith Trepanier - Chief of Safety Andrew Marreel Louis Verdetto Michael Hancock Scott Silvestry Jamie Bucio Christie Campbell Eric Moore Conference Call Participants Xuesong Wang - Morgan Stanley, Research Division Presentation Mathew Schneider Vice President of Investor Relations & Strategic Finance All right. Let's get started.

Videolar

No Data

There is no data to display

Press-relizlar

Strata Critical Medical Announces Fourth Quarter 2025 Results

Strata Critical Medical Announces Fourth Quarter 2025 Results

Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025 Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata's organic growth Full year 2025 net loss from continuing operations was $20.1 million Full year 2025 revenue and Adjusted EBITDA (1) of $197.1 million and $14.1 million, respectively, both beat the high end of our guidance range Raising full year 2026 revenue guidance to between $260 and $275 million and Adjusted EBITDA guidance to between $29 and $33 million (2) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the fourth quarter ended December 31, 2025. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.

Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditions Owned aircraft excluded from collateral package and remain unencumbered NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate of $50.0 million (the “ABL Facility”).

Strata Critical Medical Hosts 2025 Investor Day; Provides 2026 and Medium-Term Financial Guidance

Strata Critical Medical Hosts 2025 Investor Day; Provides 2026 and Medium-Term Financial Guidance

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company") is hosting its 2025 Investor Day today at the Nasdaq MarketSite in New York City. The event features presentations by leaders across the business and begins at 2:00pm ET.

Strata Critical Medical Announces Third Quarter 2025 Results

Strata Critical Medical Announces Third Quarter 2025 Results

Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year period Medical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition (1) Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025 (1) Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA range Investor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the third quarter ended September 30, 2025. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.